Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:7
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源
LIPIDS IN HEALTH AND DISEASE | 2015年 / 14卷
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] METABOLIC SYNDROME AND INSULIN RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C
    Baizhanova, Zh Zh
    Ignatova, T. M.
    Nekrasova, T. P.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (10) : 51 - 56
  • [32] Relationships among insulin resistance, obesity, diagnosis of the metabolic syndrome and cardio-metabolic risk
    Salazar, Martin R.
    Carbajal, Horacio A.
    Espeche, Walter G.
    Dulbecco, Carlos A.
    Aizpurua, Marcelo
    Marillet, Alberto G.
    Echeverria, Raul F.
    Reaven, Gerald M.
    DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (02) : 109 - 116
  • [33] Insulin Resistance and the Metabolic Syndrome Are Associated With Arterial Stiffness in Patients With Chronic Kidney Disease
    Chan, Doris T.
    Watts, Gerald F.
    Irish, Ashley B.
    Ooi, Esther M. M.
    Dogra, Gursharan K.
    AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (09) : 1155 - 1161
  • [34] Management of Cardiovascular Risk Associated with Insulin Resistance, Diabetes, and the Metabolic Syndrome
    Mehta, Adi
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 61 - 70
  • [35] Metabolic syndrome and the risk of coronary artery disease among the physicians
    Tangjitgamol, Siriwan
    Udayachalerm, Wasan
    Preeyanont, Piyanart
    Kaewwanna, Watcharagan
    Ativanichayapong, Natapon
    Wanishsawad, Chad
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (02): : 761 - 767
  • [36] Influence of Functional Nutrients on Insulin Resistance in Horses with Equine Metabolic Syndrome
    Marycz, Krzysztof
    Moll, Eberhard
    Grzesiak, Jakub
    PAKISTAN VETERINARY JOURNAL, 2014, 34 (02) : 189 - 192
  • [37] Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease
    Bays, Harold E.
    Conard, Scott E.
    Leiter, Lawrence A.
    Bird, Steven R.
    Lowe, Robert S.
    Tershakovec, Andrew M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 153 (02) : 141 - 147
  • [38] Risk of first-time heart disease higher for hormone therapy users with metabolic syndrome
    Pinkerton, JoAnn V.
    Pastore, Lisa M.
    Johns, Dearing W.
    Tucker, Amy L.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (03): : 244 - 247
  • [39] Coronary Heart Disease at the Patient With Metabolic Syndrome: Strategy of Antianginal Therapy
    Poteshkina, N. G.
    Troshina, A. A.
    KARDIOLOGIYA, 2016, 56 (04) : 91 - 95
  • [40] Metabolic syndrome and mortality in stable coronary heart disease: Relation to gender
    Kragelund, Charlotte
    Kober, Lars
    Faber, Jens
    Steffensen, Rolf
    Hildebrandt, Per
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 121 (01) : 62 - 67